Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors’ adherence to warfarin therapy recommendations
- 515 Downloads
Little is known about prescription trends in atrial fibrillation (AF) in primary health care in Sweden.
The aim was to study time trends in pharmacotherapy, in men and women with AF. We also aimed at studying doctors’ adherence to CHADS2 for prescribing warfarin. CHADS2 assesses stroke risk by presence of known risk factors, i.e., congestive heart failure, hypertension, age >75 years, diabetes, previous stroke and transient ischemic attack.
Data were obtained from primary health care records that contained individual clinical data. In total, 371,036 patients were included in the sample from 2002, and 424,329 patients were included in the sample from 2007. The study population consisted of individuals aged 45+ years who were diagnosed with AF in 2002 (1,330 men and 1,096 women) and 2007 (2,748 men and 2,234 women). The pharmacotherapies prescribed in 2002 and 2007 were analyzed separately in men and women. Logistic regression was used to calculate the association between the CHADS2 score and prescribed warfarin treatment.
Selective beta-blockers, anti-coagulant therapy and lipid-lowering drugs were prescribed more frequently in 2007 than in 2002. In 2007, antithrombotic and RAS-blocking agents were prescribed more frequently to men, whereas beta-1 selective beta-blockers were prescribed more frequently to women. There was no consistent association between the CHADS2 score and prescribed warfarin treatment.
Pharmacotherapy of AF has improved over time, though CHADS2 guidelines need to be implemented systematically in primary health care in Sweden to decrease the risk of stroke and improve quality of life in patients with AF.
KeywordsAtrial fibrillation Pharmacotherapy Gender Warfarin CHADS2 Sweden
This work was supported by grants to Kristina Sundquist and Jan Sundquist from the Swedish Research Council (K2005-27X-15428-01A, 2008-3110 and 2008-2638), the Swedish Council for Working Life and Social Research (2006-0386, 2007-1754 and 2007-1962) and the Swedish Research Council Formas (2006-4255-6596-99 and 2007-1352).
- 5.Friberg J, Scharling H, Gadsboll N, Truelsen T, Jensen GB (2004) Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am J Cardiol 94(7):889–894. doi: 10.1016/j.amjcard.2004.06.023 PubMedCrossRefGoogle Scholar
- 6.van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE (2009) Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 40(4):1410–1416. doi: 10.1161/STROKEAHA.108.526988 PubMedCrossRefGoogle Scholar
- 11.Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, Selby JV, Singer DE (2000) Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation 102(1):11–13PubMedCrossRefGoogle Scholar
- 25.Chan JD, Rea TD, Smith NL, Siscovick D, Heckbert SR, Lumley T, Chaves P, Furberg CD, Kuller L, Psaty BM (2005) Association of beta-blocker use with mortality among patients with congestive heart failure in the Cardiovascular Health Study (CHS). Am Heart J 150(3):464–470. doi: 10.1016/j.ahj.2004.12.022 PubMedCrossRefGoogle Scholar
- 28.Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 112(12):1687–1691. doi: 10.1161/CIRCULATIONAHA.105.553438 PubMedCrossRefGoogle Scholar
- 29.Lip GY, Frison L, Halperin JL, Lane DA (2010) Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41(12):2731–2738. doi: 10.1161/STROKEAHA.110.590257 PubMedCrossRefGoogle Scholar
- 30.Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263–272. doi: 10.1378/chest.09-1584 PubMedCrossRefGoogle Scholar
- 31.Sundquist K, Chaikiat A, Leon VR, Johansson SE, Sundquist J (2011) Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: a Swedish study from 25 primary health-care centres. Diabetes Metab Res Rev 27(3):244–254. doi: 10.1002/dmrr.1161 PubMedCrossRefGoogle Scholar